Vericiguat 2.5mg Tablets

Vericiguat 2.5mg is a soluble guanylate-cyclase stimulator used alongside other heart-failure medicines in adults with symptomatic chronic heart failure and reduced ejection fraction after a recent worsening event. It is an add-on treatment for longer-term outcomes, not immediate relief of fluid overload.
Take once daily with food. Treatment is increased gradually, usually at about two-week intervals, as blood pressure and tolerability allow. If swallowing is difficult, the tablet can be crushed and mixed with water immediately before taking it.
Vericiguat directly stimulates soluble guanylate cyclase and enhances its response to nitric oxide. This increases cyclic GMP, supporting relaxation of blood vessels and signalling relevant to heart and vascular function.
Low blood pressure, dizziness and anaemia are important adverse effects. Fainting, severe weakness, worsening breathlessness or symptoms of significant blood loss need medical assessment.
Do not use during pregnancy because fetal harm is possible. Effective contraception is needed during treatment and for one month afterwards. Do not combine with another soluble guanylate-cyclase stimulator such as riociguat. PDE5 inhibitors such as sildenafil or tadalafil can add hypotension. Blood pressure and haemoglobin guide follow-up.
In the studied heart-failure population, it reduces the combined risk of cardiovascular death or heart-failure hospitalisation when added to established treatment. It does not replace the other components of heart-failure care.
Gradual titration allows blood pressure and symptoms to be assessed before moving to a higher daily amount.
No. It is not a diuretic and does not quickly remove excess fluid. New swelling or rapid weight gain may require adjustment of the fluid-management plan.
Both can increase the risk of symptomatic low blood pressure. They should not be added to this heart-failure regimen independently.
Anaemia can occur and may worsen tiredness or breathlessness. A haemoglobin result helps distinguish it from other causes of heart-failure symptoms.
Reduced ejection fraction: reduced proportion of blood pumped out by the left ventricle; Soluble guanylate cyclase: an enzyme generating cyclic GMP; Nitric oxide: a signalling molecule involved in blood-vessel relaxation; Titration: gradual adjustment of a dose; Anaemia: a reduced haemoglobin level or red-cell oxygen-carrying capacity; AR: Vericiguat 2.5mg أقراص; FR: Vericiguat 2.5mg comprimés; PT: Vericiguat 2.5mg comprimidos; ES: Vericiguat 2.5mg comprimidos; RU: Vericiguat 2.5mg таблетки; ID: Vericiguat 2.5mg tablet; VI: Vericiguat 2.5mg viên nén; MS: Vericiguat 2.5mg tablet; TL: Vericiguat 2.5mg tableta; ZH-SG: Vericiguat 2.5mg 片剂
International B2B Enquiry
Send a structured B2B enquiry for Vericiguat 2.5mg Tablets under Cardiac Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Vericiguat 2.5mg Tablets